Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Severe SARS‐CoV‐2 patients develop a higher specific T‐cell response

Julie Demaret 1, 2, * Guillaume Lefevre 1, 2 Fanny Vuotto 3 Jacques Trauet 1, 2 Alain Duhamel 4 Julien Labreuche 4 Pauline Varlet 1, 2 Arnaud Dendooven 1, 2 Sarah Stabler 5 Benoit Gachet 3 Jules Bauer 3 Brigitte Prevost 6 Laurence Bocket 6 Enagnon-Kazali Alidjinou 6 Marc Lambert 7, 8 Cecile Yelnik 7, 8 Bertrand Meresse 2 Laurent Dubuquoy 2 David Launay 2, 7 Sylvain Dubucquoi 1, 2 David Montaigne 9 Eloise Woitrain 9 Francois Maggiotto 2 Mohamed Bou Saleh 2 Isabelle Top 1 Vincent Elsermans 1 Emmanuelle Jeanpierre 9 Annabelle Dupont 9 Sophie Susen 9 Thierry Brousseau 3 Julien Poissy 10 Karine Faure 5 Myriam Labalette 1, 2 For The Lille Covid Research Network (licorne)
Abstract : Objectives : Assessment of the adaptive immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial for studying long-term immunity and vaccine strategies. We quantified IFNγ-secreting T cells reactive against the main viral SARS-CoV-2 antigens using a standardised enzyme-linked immunospot assay (ELISpot). Methods : Overlapping peptide pools built from the sequences of M, N and S viral proteins and a mix (MNS) were used as antigens. Using IFNγ T-CoV-Spot assay, we assessed T-cell and antibody responses in mild, moderate and severe SARS-CoV-2 patients and in control samples collected before the outbreak. Results : Specific T cells were assessed in 60 consecutive patients (mild, n = 26; moderate, n = 10; and severe patients, n = 24) during their follow-up (median time from symptom onset [interquartile range]: 36 days [28;53]). T cells against M, N and S peptide pools were detected in n = 60 (100%), n = 56 (93.3%), n = 55 patients (91.7%), respectively. Using the MNS mix, IFNγ T-CoV-Spot assay showed a specificity of 96.7% (95% CI, 88.5–99.6%) and a specificity of 90.3% (75.2–98.0%). The frequency of reactive T cells observed with M, S and MNS mix pools correlated with severity and with levels of anti-S1 and anti-RBD serum antibodies. Conclusion : IFNγ T-CoV-Spot assay is a reliable method to explore specific T cells in large cohorts of patients. This test may become a useful tool to assess the long-lived memory T-cell response after vaccination. Our study demonstrates that SARS-CoV-2 patients developing a severe disease achieve a higher adaptive immune response.
Liste complète des métadonnées

https://hal.univ-lille.fr/hal-03288894
Contributeur : Lilloa Université de Lille <>
Soumis le : vendredi 16 juillet 2021 - 15:29:49
Dernière modification le : lundi 19 juillet 2021 - 11:46:04

Fichier

cti2.1217.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Licence


Distributed under a Creative Commons Paternité - Pas d'utilisation commerciale - Pas de modification 4.0 International License

Identifiants

Collections

Citation

Julie Demaret, Guillaume Lefevre, Fanny Vuotto, Jacques Trauet, Alain Duhamel, et al.. Severe SARS‐CoV‐2 patients develop a higher specific T‐cell response. Clinical and Translational Immunology, Nature Publishing Group, 2020, 9 (12), pp.e1217. ⟨10.1002/cti2.1217⟩. ⟨hal-03288894⟩

Partager

Métriques

Consultations de la notice

38

Téléchargements de fichiers

42